View Virpax Pharmaceuticals Inc price, streaming chart and supplemental info. Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. Phone Number 610.727.4597. For financial reporting, their fiscal year ends on December 31st. Company profile page for Virpax Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information The Stock rose vividly during the last session to $5.22 after opening rate of $4.376 while the lowest price it went was recorded $4.2649 before closing at $4.41. Virpax… Press Release reported on 06/02/21 that Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9(th) at 4:30 PM ET In addition, Virpax has granted the underwriters a 30-day option to purchase up to an additional 270,000 shares of common stock to cover over … ACCESSWIRE +5.74%. If you are looking for stocks with good return, Virpax Pharmaceuticals Inc stock can be a bad, high-risk 1-year investment option. Our Virpax Pharmaceuticals Inc (VRPX) share price forecast provides you with the next 12-months stock price predictions, calculated by top analysts within the industry. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). VIRPAX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-1510982 (State or other jurisdiction of incorporation or organization) (I.R.S. Stocks under 5 dollars, stocks for 5 USD. Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax® Pharmaceuticals, Inc., today announced that the Company has engaged Torreya Capital, LLC to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets. Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) went up by 1.00% from its latest closing price compared to the recent 1-year high of $8.24. Sample 10-K Year-over-Year (YoY) Comparison. has filed to raise $15 million in an IPO of its common stock, Virpax Pharmaceuticals, Inc. - 8-K, Current Report: 19.04. Virpax Pharmaceuticals Inc Stock Ownership Add to Watchlist. Virpax Pharmaceuticals had issued 1,800,000 shares in its initial public offering on February 17th. The total size of the offering was $18,000,000 based on an initial share price of $10.00. After the expiration of Virpax Pharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Virpax Pharmaceuticals, Inc. Form 10-K ... there was no established public market for the registrant’s Common Stock. We do not make recommendations or offer investment, tax or legal advice. The latest Virpax Pharmaceuticals Inc USD0.00001 share price. VRPX on StockCharts.com. The company’s stock price has collected 7.95% of gains in the last five trading sessions. VRPX updated stock price target summary. Virpax Pharmaceuticals' lock-up period expires on Monday, August 16th. Virpax Pharmaceuticals had issued 1,800,000 shares in its initial public offering on February 17th. The total size of the offering was $18,000,000 based on an initial share price of $10.00. Royal Caribbean Group (RCL) saw an uptrend of 2.86% in the recent trading with $89.15 being its most recent. Common Stock . VIRPAX PHARMACEUTICALS, INC. This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”). WEST CHESTER, PA / ACCESSWIRE / February 16, 2021 / Virpax ® Pharmaceuticals Inc. ('Virpax' or the 'Company') (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 … The MarketWatch News Department was not … Currently at 0.54 is the 14-day ATR for Virpax Pharmaceuticals Inc. (VRPX). Virpax Pharmaceuticals, Inc. (VRPX) Stock Price: $4.02 USD -0.03 (-0.79%) Updated Jun 18, 2021 12:20 PM EDT - Market open. Let’s start up with the current stock price of Virpax Pharmaceuticals Inc. (VRPX), which is $5.14 to be very precise. Shares of VRPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Virpax Pharmaceuticals' stock price today? The current price level -10.17% lower than the highest price of $99.24 marked by the stock while trading over the past 52-weeks, whereas it is 300.67% higher than the lowest price of $22.25 the company dropped to over past 52-weeks. WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ('Virpax' or the 'Company') (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 million, … 09:00 AM ET. Today's Range. 09:00 AM ET. Virpax Announces Results of Probudur(TM) in Animal Study ACCESSWIRE. ... 'Broker forecast' and 'Recent trades' provided by MoneyAM. $4.3301. VRPX: Virpax Pharmaceuticals, Inc. - Earnings Announcements. Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Virpax Pharmaceuticals, including Galmed Pharmaceuticals (GLMD), Cleveland BioLabs (CBLI), Aridis Pharmaceuticals (ARDS), … Get the hottest s Virpax Announces Results of Probudur (TM) in Animal Study. WEST CHESTER, PA / ACCESSWIRE / March 2, 2021 / Virpax ® Pharmaceuticals Inc. ('Virpax' or the 'Company') (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No. Virpax Pharmaceuticals, Inc. is focused on developing branded prescription products and providing more efficient drug treatments using its proprietary cutting-edge … Insider buying vs selling Have Virpax Pharmaceuticals Inc insiders been buying or selling? Comments. ex-10.5 employment agreement by and between virpax pharmaceuticals, inc. and anthony mac ex-10.6 consulting agreement by and between SEC Filings for Virpax Pharmaceuticals Inc. BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma -- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals (NASDAQ:VRPX) Vs. GLMD, CBLI, ARDS, CYAD, MNPR, and ASRT. The relative strength of a dividend stock indicates whether the stock is uptrending or not. Stock price predictions, forecasts with 14 days, 3 months, 6 months, 1 year and 5 years timeline. Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals Inc. (VRPX) shares reached a high of $6.00 and dropped to a low of $4.50 until finishing in the latest session at $4.63. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Volume201,832 shs. Our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide. Pain is a universal condition, while the perception of … ACCESSWIRE +5.74%. Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments.“We successfully completed our initial public offering (IPO) of 1,800,000 shares of our common stock … VIRPAX PHARMACEUTICALS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for VIRPAX PHARMACEUTICALS, INC. Stock | VRPX | US9282511073 About the Dune Acquisition Corporation – Warrants (17/12/2025) stock forecast. Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) went up by 4.63% from its latest closing price compared to the recent 1-year high of $8.24. Virpax Pharmaceuticals reports Q1 results: 18.05. Overview Earnings Dividend Ownership. Employer Identification Number) 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 (Address of principal executive offices) (Zip code) (610) 727-4597 Monday, April 19, 2021. Compare. 10/09/2020. Virpax ® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX ), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of an animal study model for MMS019, its anti-viral product candidate for respiratory viruses. 02-18 sec.gov. View today's stock price, news and analysis for Virpax Pharmaceuticals Inc. (VRPX). Virpax Pharmaceuticals, Inc ... Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products. * Virpax Pharmaceuticals Inc (VRPX) - OPERATING LOSS FOR Q1 OF 2021 WAS ABOUT $2.3 MILLION, AS COMPARED TO $0.6 MILLION FOR SAME PERIOD A YEAR AGO. Press Release reported on 03/22/21 that Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Probudur(TM) for Postoperative Pain Data is currently not available. Free forex prices, toplists, indices and lots more. Average Volume235,972 shs. Should you be buying VRPX stock or one of its competitors? Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. In addition, Virpax has granted the underwriters a 30-day option to purchase up to an additional 270,000 shares of common stock to cover over … Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. Get Our PREMIUM Forecast Now, from ONLY $7.49! 10/09/2020. 50-Day Range. ex-10.4 form of incentive stock option award under 2017 equity incentive plan. Virpax Pharmaceuticals Announces Closing of Initial Public Offering. During the day the stock fluctuated 6.91% from a day low at $4.05 to a day high of $4.33. Sell. ex-10.3 form of nonqualified stock option award under 2017 equity incentive plan. The price has been going up and down for this period, and there has been a -7.95% loss for the last 2 weeks. Financials. $3.85 $6.00. BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax ® Pharmaceuticals, Inc. ('Virpax' or the 'Company') (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected Probudur™, Virpax's liposomal … Virpax Pharmaceuticals Inc real time quote is equal to 4.990 USD at 2021-03-06, but your current investment may be devalued in the future. Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) stock closed at 4.62 per share at the end of the most recent trading day (a -5.33 % change compared to the prior day closing price) with a volume of 59.16K shares and market capitalization of 22.92M.Is a component of indices and it is traded on NASDAQ exchange. Buy. 10842745 entitled, 'Composition of matter comprising liposome embedded in a … Virpax Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. Symbol; ... Stock Data API from IexCloud; Investing in securities products involves risk, including possible loss of principal. The company is offering 31 million shares at $32 to $34 each, meaning it could raise as much as $1.05 billion if the stock sells at the top of that range. ET. Selected key stats of Virpax Pharmaceuticals, Inc. (VRPX) including 10 year stock price and latest news. Thani Jambulingam: Director: 2021-02-17: 100: Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) today announced the pricing of its initial public offering of 1,800,000 shares of its common stock … Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's … Virpax Pharmaceuticals, Inc. CIK: 1708331. 333-253176 1,800,000 Shares Common Stock Virpax Pharmaceuticals, Inc This is a firm commitment initial public offering of 1,800,000 shares of Virpax Pharmaceuticals, Inc. common stock. PROSPECTUS Filed Pursuant to Rule 424 (b) (4) Registration No. Ticker: VRPX. +0.2801 (+6.92%) DATA AS OF Jun 16, 2021 11:14 AM ET. Stock analysis for Virpax Pharmaceuticals Inc (VRPX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Virpax Pharmaceuticals Stock Forecast, Price & News $4.05-0.03 (-0.74 %) (As of 06/17/2021 12:00 AM ET) Add. It is expected to trade on the New York Stock Exchange under the symbol OSCR. But evaluating the performance of companies like Virpax Pharmaceuticals can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Find the latest Virpax Pharmaceuticals, Inc. (VRPX) stock quote, history, news and other vital information to help you with your stock trading and investing. Monday, April 05, 2021. Virpax Pharmaceuticals Inc. (VRPX) shares reached a high of $6.00 and dropped to a low of $4.50 until finishing in the latest session at $4.63. View Virpax Pharmaceuticals Inc price, streaming chart and supplemental info. Oscar is scheduled to price its deal on March 2, and trade the next day, one person said. Virpax Pharmaceuticals is committed to developing products that manage pain and all its complexities, while minimizing risks to patients and society. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Nasdaq Listed. Virpax Pharmaceuticals Inc 1. These milestone payments relate to the licensing of Envelta™ for the treatment of non-cancer pain and … The major determining factor in this rating is whether the stock is trading close to its 52-week-high. Overview. Stay up to date with lastest Earnings Announcements for Virpax Pharmaceuticals, Inc. from Zacks Investment Research Business Wire – 8:00 AM ET 04/22/2021. Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts BusinessWire - BZX. Read market forecasts, VRPX financials, economic background and market news Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur. The Virpax Pharmaceuticals, Inc. stock price fell by -0.74% on the last day (Thursday, 17th Jun 2021) from $4.08 to $4.05. Reviewing Business Analytics and Forecast modeling ... Virpax shall grant Consultant stock options in Virpax equivalent to 75,000 shares of Virpax stock. Zeit Aktuelle Nachrichten; 18.05. Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer. Before founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Registration Statement. The company belongs in the Biotechnology industry, Healthcare sector and … Virpax Pharmaceuticals, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Nasdaq 100. Published: April 5, 2021 at 9:00 a.m. VRPX: Get the latest Virpax Pharmaceuticals stock price and detailed information including VRPX news, historical charts and realtime prices. Virpax Pharmaceuticals Inc. (VRPX) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. View differences made from one to another to evaluate Virpax Pharmaceuticals, Inc.'s financial trajectory. Let’s start up with the current stock price of Virpax Pharmaceuticals Inc. (VRPX), which is $5.14 to be very precise. Showing 501-600 of 9,781 items. $4.05 $4.33. Information is provided 'as-is' and solely for info See Virpax Pharmaceuticals, Inc. (VRPX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. $3.79 $8.24. Virpax Pharmaceuticals Inc (VRPX) $4.46 0.15 (3.44%) 13:00 EDT VRPX Stock Quote Delayed 30 Minutes ... VRPX Stock Predictions, Articles, and Virpax Pharmaceuticals Inc News Stock Price Prediction: Update at 5:00pm EST Read market forecasts, VRPX financials, economic background and market news Virpax Pharmaceuticals (NASDAQ: VRPX) is $4.94 last updated Thu Apr 01 2021 19:57:56 GMT+0000 (Coordinated Universal Time). 52-Week Range. Get the hottest s Form 10-K filed by Virpax Pharmaceuticals, Inc. with the security and exchange commission. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The company’s stock price has collected -6.31% of loss in the last five trading sessions. LONDON, UK / ACCESSWIRE / March 1, 2021 / Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX). Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. 1. Virpax Pharmaceuticals, Inc. ... an unsolicited non-binding offer to acquires all shares of its common stock for $9 per ... reported downbeat Q4 sales and issued weak FY22 earnings forecast. N/A. Its products include DSF100, Probudur, Epoladerm and NES100. Virpax Pharmaceuticals Inc (VRPX): * VIRPAX PHARMACEUTICALS REPORTS 2021 FIRST QUARTER RESULTS AND RECENT DEVELOPMENTS. documents---0.0012590885162354. Currently at 0.54 is the 14-day ATR for Virpax Pharmaceuticals Inc. (VRPX). Virpax Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Mr. As of 2021 June 11, Friday current price of DUNEW stock is 0.680$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Establishment and Purpose . Virpax Pharmaceuticals Announces Closing of Initial Public Offering. (1) Covers 1,009,505 shares of common stock issuable under the Virpax Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). COMPENSATION COMMITTEE CHARTER as of August 7, 2020 The Compensation Committee (the “Committee”) was created by the Board of Directors of the Company (the “Board”) to: ... the authority to make grants and awards of stock rights or options to any non-Section 16 officer of the Company under It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Virpax Pharmaceuticals (VRPX) stock price, charts, trades & the US's most popular discussion forums. The registrant’s Common Stock began trading on the NASDAQ Capital Market on February 24, 2021. Share . The stock price for . The Stock rose vividly during the last session to $5.22 after opening rate of $4.376 while the lowest price it went was recorded $4.2649 before closing at $4.41. Description. S-1. March 1, 2021 - 11:15 am. Contact Email Info@virpaxpharma.com. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the Virpax Pharmaceuticals Inc stock. BRIEF-Virpax Pharmaceuticals Reports Q1 Operating Loss Of $2.3 Mln Tue 1:09pm News NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:50 AM Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. But evaluating the performance of companies like Virpax Pharmaceuticals can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Virpax’s MMS019 Reduced Nasal and Brain Viral Load in Animal Study BusinessWire - BZX. VIRPAX PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN . 333-249417 Registration No. Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Add to Watchlist. Name Role Date Shares Price Value; Gary S. Jacob: Director: 2021-02-17: 3,500: $6.79: $23.76k Buy. Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Large Bees In Washington State, Afc Club Ranking Mohun Bagan, Biblical Prep 4 Letters, Suffuse With Colour Crossword Clue, Is The Lsat An Intelligence Test, Fedloan Servicing Pheaa, Famous People From New Jersey, Sonicwall Cannot Add User To Group,
